Introduction {#s1}
============

The CRISPR/Cascade 9 system is a RNA-guided system naturally used by archaea and bacteria for protection/immunity against invading viruses or plasmids and provides an interesting example of co-evolution between hosts and viruses. The simplicity of the CRISPR/Cascade 9 system has enabled the development of a reliable and efficient genome editing tool which has revolutionized the ability to manipulate genes in many different organisms (Peng et al., [@B65]). The CRISPR/Cascade 9 system comprises three components, small crRNAs (CRISPR RNAs), tracrRNA (auxiliary trans-activating crRNA), and the CRISPR associated protein 9 (Cascade 9). Cascade 9 is a RNA guided dsDNA nuclease which together with the crRNA/tracrRNA complex containing the target sequence of choice, termed the protospacer, is responsible for cleaving the targeted DNA strand using its HNH and RuvC nuclease domains. Cascade 9 also requires a small sequence downstream of the hybrid region called PAM (protospacer adjacent motif) that essentially behaves as a targeting component. The principle of the CRISPR/Cascade 9 system for targeted genome editing is illustrated in Figure [1](#F1){ref-type="fig"}. A synthetic fusion between crRNA and tracrRNA harboring a site-specific 20 bp single guide RNA (sgRNA) is constructed for the desired target site. The function of promoters directing the synthesis of sgRNAs is modulated by the number of guanidine residues at the 5′ end of the transcript. A single "G" is present in RNA polymerase III promoters, whereas two G\'s are found in SP6, T3, and T7 promoters. A separate vector drives expression of Cascade 9. The site-specific 20-nucleotides sequence of the sgRNA directs the Cascade 9 nuclease to its target. Double-strand breaks (DSBs) induced by Cascade 9 are re-ligated by the error-prone non-homologous end joining (NHEJ) pathway often resulting in deletions or insertions leading to loss of function (Figure [2](#F2){ref-type="fig"}). Structural and functional analyses have demonstrated that the PAM-binding domain of Cascade 9 interacts with the non-complementary strand GG dinucleotide via conserved arginine residues in the carboxy-terminal domain of Cascade 9, suggesting possibilities for overcoming the PAM-dependent limitation of targetable sequences (Anders et al., [@B2]). Accordingly, engineered SpCascade 9 and SaCascade 9 have recently been developed by utilizing bacterial selection-based directed evolution to recognize alternative PAMs (Kleinstiver et al., [@B40]). The SpCascade 9-VQR and SpCascade 9-EQR variants primarily recognize 5′-NGAN-3′ and 5′-NGNG-3′ PAMs, while the SpCascade 9-VRER variant is specific for the 5′-NGCG-3′ PMA motif, and using a structure-guided design strategy FnCascade 9 has been modified to recognize YG PAM sequences rather than NGG (Hirano et al., [@B33]).

![Schematic illustration of the CRISPR/Cascade 9 system and the genome editing process. **(A)** sgRNA is designed to target the genome with the standard sequence of 5′-GG(G/A)-N17/18-NGG-3′ at the 5′ of a PAM (NGG). **(B)** Map of the pSP6-2sNLS-SpCas9 vector. **(C)** Map of the pMD19-T sgRNA scaffold vector used to produce sgRNA driven by the T7 promoter.](fgene-09-00240-g0001){#F1}

![The basic working principle of the sgRNA-editing technology. Double strand break (DSB) repair can be used to target defined genomic modification. The double strand break (DSB) induced by the Cascade 9/sgRNA complex can be repaired through non-homologous end joining (NHEJ) or homologous recombination (HR). This can result in short insertions or deletions at the target site (left), deletions of larger genomic regions when two cuts are made (middle) or homologous repair with a desired template (brown). This can be used to alter the genome in a variety of different ways (bottom).](fgene-09-00240-g0002){#F2}

Due to the simplicity and effectiveness of the CRISPR/Cascade 9 system, it is currently extensively used for genome editing in different organisms. Unlike protocols based on zinc-finger nucleases (ZNFs) and transcription activator-like effector nucleases (TALENs), protein engineering is not required, and it is possible to use sgRNAs targeting multiple sites. However, it should be noted that off-target modifications can be observed. The extent to which such off-target events occur seems to be correlated with the size and complexity of the targeted genome (Wei et al., [@B94]). Thus, reflecting genome sizes off-target events are more likely to occur in monocotyledonous plants than in dicotyledonous plants, and in vertebrates compared to invertebrates (Gregory et al., [@B27]) (Li and Du, [@B51]). In principle, the CRISPR/Cascade 9 system enables genome editing in embryos which, however, still is controversial. Furthermore, a number of technical issues still remain to be addressed (Chrenek et al., [@B14]), and specific deign for effective genome editing in embryos of different organisms may be required. For instance, the choice of delivery of the CRISPR/Cascade 9 system, electroporation, microinjection, and vector types used *in vitro* and *in vivo* remains challenging. In addition, toxicity of vectors and other components of CRISPR/Cascade 9 system also constitutes a challenge and needs to be addressed (Bassett et al., [@B6]). However, the successful correction of a gene in 42 out of 58 human embryos was recently reported (Ma et al., [@B57]).

Conventional gene disruption approaches such as gene deletion, gene insertion or frame-shift in coding sequences are all expensive and labor-intensive due to the inefficient homologous recombination-based protocols (Cong et al., [@B16]), and the use of alternative protocols using meganucleases has been limited due to the complex mechanism of genome editing associated with this approach (Silva et al., [@B81]). By contrast, already now the CRISPR/Cascade 9 system has been used for genome editing in a large variety of species as summarized in Table [1](#T1){ref-type="table"}. Here we review different approaches and challenges associated with the use of the CRISPR/Cascade 9 system and discuss opportunities and future directions including ethical concerns.

###### 

Examples of CRISPR/ Cascade 9-mediated genome editing in human cells and model organisms.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Different approaches**                  **Organisms**                  **Genes**                                            **References**
  ----------------------------------------- ------------------------------ ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  Gene knockout                             **INVERTERBRATES**                                                                  

                                                Drosophila                 *Yellow, white, AGO1*                                Bassett et al., [@B6], [@B7]

                                                Silkworm                   *BmWnt1, BmBLOS2*\                                   Wang et al., [@B93]; Zhang et al., [@B110]\
                                                                           *Bm-ok, BmKMO, BmTH, and Bmtan*                      Wei et al., [@B94]

                                                *Caenorhabditis elegans*   *csr-1, mes-6, dpy-3, unc-1*                         Cho et al., [@B13]; Chen et al., [@B10]

                                                Yeast                      *ADE2*                                               Giersch and Finnigan, [@B25]

                                            **VERTEBRATES**                                                                     

                                                Human                      *H69, DMRT1, DMRT3, NF1, MED12*,\                    Shalem et al., [@B76]; Shetty and Inamdar, [@B78]; Tahara et al., [@B83]; Wang et al., [@B89]; Inui et al., [@B36]; Wills et al., [@B95]
                                                                           *NF2, CUL3, TADA2B, TADA1, MAGEC2, S100A4, OCIAD1*   

                                                Zebrafish                  *cyp19a1a, valopa, valopb*                           Hang et al., [@B30]; Lau et al., [@B45]

                                                Mouse                      *Rp9*                                                Lv et al., [@B56]

                                                Chicken                    *Stra8, Myostatin*                                   Lee et al., [@B47]; Zhang et al., [@B109]

                                                Monkey                     *Ppar-γ, Rag1*                                       Niu et al., [@B61]

                                            **PLANTS**                                                                          

                                                *Arabidopsis*\             *OsSWEET14 and OsSWEET11, PDS3, TTG1, IAA2, CDK*     Jiang et al., [@B38]; Endo et al., [@B19]; Ryder et al., [@B74]; Tsutsui and Higashiyama, [@B86]
                                            Tobacco\                                                                            
                                            Sorghum and Rice                                                                    

  Gene knock-in                             **INVERTERBRATES**                                                                  

                                                Drosophila                 *nanos, yellow locus, white locus*                   Xue et al., [@B97]; Port et al., [@B69]

                                                Silkworm                   *Bmku70*                                             Ma et al., [@B58]

                                                *Caenorhabditis elegans*   *unc-119*                                            Zhao et al., [@B111]

                                            **VERTERBRATES**                                                                    

                                                Human                      *DACT1, IFIT1and EGR1*                               Zhang et al., [@B107]

                                                Zebrafish                  *zebrafish th, tardbp, fus*                          Armstrong et al., [@B3]

                                                Mouse                      *Rosa26, KRAS, p53,LKB1*                             Li et al., [@B50]

                                                Chicken                    *yRad52*                                             Platt et al., [@B67]; Chu et al., [@B15]

                                                Pig                        *COL1A*                                              Park et al., [@B63]; Wang et al., [@B90]

                                            **PLANTS**                                                                          

                                                *Arabidopsis*              *PDS3, AtFLS2*                                       Li et al., [@B49]

                                                Tobacco                    *No*                                                 

                                                Rice                       *WDV*                                                Wang et al., [@B92]

  Gene Knockdown and silencing approaches   **INVERTERBRATES**                                                                  

                                                *Drosophila*               *roX1, roX2*,                                        Ghosh et al., [@B24]

                                                *Caenorhabditis elegans*   *TRHR-1*                                             

                                                Silkworm                   No                                                   Van Sinay et al., [@B87]

                                            **VERTERBRATES**                                                                    

                                                Human\                     *EPHA1*\                                             Cui et al., [@B17]\
                                            Zebrafish\                     *mmp21*\                                             Guimier et al., [@B28]\
                                            Mouse\                         *Nrl*\                                               Yu et al., [@B105]
                                            Chicken\                       No\                                                  
                                            Pig                            No                                                   

  Gene correction                           **INVERTERBRATES**                                                                  

                                                *Drosophila*               No                                                   

                                                *Caenorhabditis elegans*   No                                                   

                                                Silkworm                   No                                                   

                                            **VERTERBRATES**                                                                    

                                                Human                      *MYBPC3*                                             Ma et al., [@B57]

                                                Zebrafish                  No                                                   

                                                Mouse                      *Hemophilia B, Pde6b*                                

                                                Chicken                    No                                                   Huai et al., [@B35]

                                                Pig                        No                                                   

  Conditional approaches                    **INVERTERBRATES**                                                                  

                                                *Drosophila*               *bam, nos, cid, ms(3)k81, wg*                        Port et al., [@B68]; Xue et al., [@B97]

                                                *Caenorhabditis elegans*   *dpy-5, lon-2, unc-76*                               

                                                Silkworm                   *No*                                                 Shen et al., [@B77]

                                            **VERTERBRATES**                                                                    

                                                Human                      *puroR, Ctnnb1*                                      Shen et al., [@B77]

                                                Zebrafish                  *tyr, insra; insrb, ascl1a*                          

                                                Mouse                      *Mecp2, Ispd, Kras; p53;*\                           Yin L. et al., [@B103]
                                                                           *Lkb 1*                                              

                                                Chicken                    *No*                                                 Yang et al., [@B98]; Lee and Lloyd, [@B46]; Platt et al., [@B67]

                                                Pig                        *PFFs*                                               Liu et al., [@B53]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gene disruption approaches in organisms {#s2}
=======================================

Knockout approaches
-------------------

The use of the CRISPR/Cascade 9 system technology is rapidly increasing using different model systems and has allowed effective whole-genome screening for identification of therapeutic targets (see Table [1](#T1){ref-type="table"}). Candidate gene knockout is a powerful approach as it may directly identify a phenotype resulting from the loss-of-function of the targeted gene. The CRISPR/Cascade 9-mediated knockout technology has been used in different genetic model organisms, including insects (Liu Y. et al., [@B55]; Xue et al., [@B97]), *Caenorhabditis elegans* (Liu P. et al., [@B54]) and humans (Tsai et al., [@B84]). Highly efficient mutagenesis of the *yellow* gene was achieved by injecting a sgRNA targeting an exon of the gene in *Drosophila* embryos (Bassett et al., [@B6]). As an example to illustrate the power of the CRISPR/Cascade 9 system, successful targeting of 14 distinct genomic loci in *Arabidopsis* with no detectable off-target events has been reported, also pointing to the CRISPR/Cascade 9 system as a powerful tool for agricultural purposes (Peterson et al., [@B66]).

Novel approaches for base-editing technology are essential for improving the efficiency of gene knockout or silencing. The recently developed WT-Cascade 9 -mediated gene knockout and CRISPR-STOP approaches, termed second generation genome editing tools, represent such two novel developments. The WT-Cascade 9 approach, which creates DSBs and indels at the target sites, allows exchange of a single specific base using the nickase activity of Cascade 9 to introduce C to T or A to G conversions at the specific target site (Gaudelli et al., [@B23]) (Komor et al., [@B41]). The CRISPR-STOP approach enables the insertion of early STOP codons in genes (Kuscu et al., [@B43]) with the codons CGA (Arg), CAG (Gln), and CAA (Gln) being effectively converted into stop codons with higher efficiency using the CRISPR-STOP approach than the WT-Cascade 9 knockout approach (Billon et al., [@B8]). Recently, Zuo et al. reported on a one--step generation of complete knockout of several genes in mouse and monkey models using multiple sgRN spaced 10--200 bp apart targeting a single key exon in each target gene. Phenotypic analysis of first generation mice revealed specific deletion of eight genes on the Y chromosome. This approach also resulted in highly-efficient gene knockout in monkeys (Zuo et al., [@B112]). Successful multiple gene knockout was further achieved by using a combination of dual sgRNAs in *C. elegans* where multiple sgRNA sequences were incorporated into a single CRISPR systems enabling selective editing and reducing off-target effect (Chen et al., [@B10]). Finally, in utero electroporation represents an interesting option for organ-specific gene knockout using the CRISPR/Cascade 9 system. As an example, Shinmyo et al. ([@B80]) reported on a highly effective knockout of the *Satb2* gene in the mouse (Shinmyo et al., [@B80]).

Knock-in approaches
-------------------

Gene knock-in in different model organisms has traditionally been based on homologous recombination (HR) and NHEJ. Knock-in based on NHEJ has to some extent reduced time-consuming labor and has improved gene knock-in in cells and animals with low HR frequency (Yoshimi et al., [@B104]). However, double-strand DNA breaks (DSB) initiated by Cascade 9 are preferentially repaired by NHEJ, which is not appropriate for knocking-in genes. DSBs may also increase homology-directed repair (HDR)-dependent gene editing and knock-in, but several studies have recently shown that HDR-mediated gene knock-in in zebra fish (Auer et al., [@B4]; Irion et al., [@B37]) and Xenopus (Shi et al., [@B79]) was ineffective using the CRISPR/Cascade 9 system. Although the molecular mechanisms underlying DSB-induced mutagenesis have been intensely investigated, a number of questions remains concerning the use of homologous and micro-homologous sequences during template change in synthesis-dependent strand annealing (SDSA) and break-induced replication (BIR). Thus, it remains to be established to what extent the molecular mechanisms of SDSA and BIR have been maintained in different eukaryotes with different genome size or structure. A few studies using human cells have demonstrated that CRISPR/Cascade 9-NHEJ may result in effective DNA insertion and that the knock-in efficiency was improved compared with a HDR-based approach (He et al., [@B31]). Still, in a lung cancer mouse model, efficient knock-in of the *KRAS, p53, and LKB1* genes by CRISPR-based HDR has offered the ability to create defined modifications in genetic sequences associated with cancer (Platt et al., [@B67]). Interestingly, suppressing the NHEJ pathway or increasing the HDR pathway has been shown to enhance nuclease-mediated knock-in efficiency both *in vitro* and *in vivo*, and studies have further shown that small molecules such as Scr7, L755507 and resveratrol may enhance HDR-dependent knock-in efficiency of the CRISPR/Cascade 9 system. Thus, the supplementation with such small molecules may also be advantageous for production of genetically modified animals (Li et al., [@B48]). It should be mentioned that Suzuki and coworkers recently designed a micro-homology-mediated end joining (MMEJ)-assisted knock-in approach and a CRISPR-MMEJ-mediated tagging approach that have been applied in a variety of settings, ranging from cell lines such as HEK293T, HeLa, CHO-K1 to silkworm, zebrafish and frog (Sakuma et al., [@B75]). This vector delivery approach is efficient for gene editing, reaching 85% efficiency (Xiong et al., [@B96]). Finally, a recently described CRISPR-mediated epitope tagging approach holds promises for efficient gene knock-in (Nitika and Truman, [@B62]). So far, NHEJ-mediated repair of CRISPR/Cascade 9-mediated insertion of large DNA fragments has not been investigated in humans, and effective knock-in in human embryonic stem cell (ESCs) still constitutes a challenge. Experiments in model organisms that combine next-generation sequencing and genomic studies are clearly warranted to address remining problems associated with the use of the CRISPR/Cascade 9 system (Rodgers and McVey, [@B72]).

Conditional approaches
----------------------

Conditional knock-out (cKO) models circumvent a number of the problems related to the use of constitutive knock-out models such as embryonic lethality. cKO methods have been used widely for achieving tissue-specific gene deletion in the mouse (Kühn et al., [@B42]) and in the zebrafish. cKO models may further aid investigation and understanding of a number of human diseases. Conditional mutant models are thus becoming indispensable tools in the biomedical field (Rosenthal and Brown, [@B73]). Conditional approaches can overcome the limitations faced by simple knockout strategies using the CRISPR/Cascade 9 system for studies on embryogenesis as they allow temporal targeting of a specific tissue/organ at determined developmental stages and enable cell lineage tracing. As illustrated in Figure [3A](#F3){ref-type="fig"}, using the DNA sequence 5′-GG(G/A)-N17/18-NGG-3′ at the 5′ of a PAM (NGG) and designed Oligo-L and Oligo-R (Figure [3B](#F3){ref-type="fig"}), a specific gene exon can be targeted by two sgRNA following microinjected of Cascade 9 and the sgRNAs (Figures [3C,D](#F3){ref-type="fig"}). It has been demonstrated that the fusion of a *FKBP12*-derived destabilizing domain to Cascade 9 alters conditional Cascade 9 expression and the temporal control of gene editing in the presence of an *FKBP12* synthetic ligand allowing investigation of the interactions between functional genes (Figure [4](#F4){ref-type="fig"}). In conclusion, the CRISPR/Cascade 9 system has successfully been used to generate conditional knock-out mice, rats and *C. elegans* (Ma et al., [@B59]), demonstrating that the CRISPR/Cascade 9 is a powerful tool for investigating the relationship between genotype and phenotype in developmental biology.

![Scheme illustrating the sgRNA structure and mechanism of the target recognition. **(A)** The target DNA sequence is 5′-GG(G/A)-N17/18-NGG-3′ at the 5′ of a PAM (NGG). **(B)** Gene Oligo-L and Gen Oligo-R were deigned. **(C)** Gene exon was targeted by two sgRNA. **(D)** Cascade 9 and sgRNAs were microinjected into the organism.](fgene-09-00240-g0003){#F3}

![Schematic illustration of the principle behind generation of a conditional allele. A gene exon was targeted by two sgRNAs (sgRNA-L and sgRNA-R) which were designed to cut both ends of the gene exon, A single ssOD was designed to carry the two FRT sequences. All constructs and cascade 9 were microinjected into the organism.](fgene-09-00240-g0004){#F4}

Gene correction approaches
--------------------------

Targeted gene correction may eventually be used for disease therapy including diseases such as muscular dystrophy, cystic fibrosis, hemophilia A and B, and Gauche disease. Previously, the cost of treatment, safety, and efficacy of gene editing has constituted huge obstacles, but some of these difficulties have now been circumvented by the development of CRISPR/Cascade 9 gene editing. For instance, Song et al. have successfully corrected mutations causing beta-thalassemia using iPSCs in combination with CRISPR/Cascade 9 without any observed off-target effects (Song et al., [@B82]). Further, the Cpf1 protein, a type V CRISPR effector, has been successfully used to induce mutations in the soybean genome (Fagerlund et al., [@B20]). Gene insertions or deletions can be introduced in cancerous cell using CRISPR/Cascade 9 technology. Thus, the CRISPR/Cascade 9 system may be used for insertion of inactivating indels in the oncogenic receptor tyrosine kinase *Erb2*, and the CRISPR/Cascade 9 technology has been applied in connection with lung cancer models and diseases including tyrosinemia and amyotrophic lateral sclerosis (Wang et al., [@B91]; Yin et al., [@B100]). In recent years, *Mycoplasma* and *Escherichia coli* genes have been edited *in vivo* in yeast cells using the CRISPR/Cascade 9 system (Tsarmpopoulos et al., [@B85]) and established standardized sequences of *S. cerevisiae* genes (selected from overexpression or gene knockdown) have been integrated into the yeast genome using the CRISPR/Cascade 9 system (Giersch and Finnigan, [@B25]). In the future, sgRNA may provide even better options for editing endogenous genomic sites and perform functional analysis of genes.

Gene correction approaches can be categorized into four types (1) endogenous gene disruption, (2) frame-shift to restore protein reading frame, (3) foreign sequence insertion using target-specific knock-in, and (4) mutated sequence substitution (Figure [5](#F5){ref-type="fig"}) (Lisa Li et al., [@B52]; Yin et al., [@B99]). According to the Online Mendelian Inheritance in Man (OMIM) database, more than 8,000 inherited monogenic diseases arising from mutations in a single gene have been identified. However, an efficient drug therapy does not exist for the majority of these diseases. Therefore, gene therapy approaches by correcting the mutated loci using the CRISPR/Cascade 9 system represents a potential powerful tool for treatment. Yet increasing the efficiency of gene correction would be required for use in the biomedical field and off-target effects are of concern in relation to safety and side effects and this raises numerous questions in relation to ethics and safety (Yin H. et al., [@B102]).

![Overview of potential genome engineering outcomes using site-specific nucleases. (Left) Nuclease-induced DNA double-strand breaks (DSBs) can be repaired by homologous recombination (HR) or error-prone non-homologous end joining (NHEJ). In the absence of donor plasmid, NHEJ-mediated repair yields short insertion or deletion mutations at the target that cause gene disruption. DNA fragments up to 14 kb have been inserted via NHEJ-mediated ligation. Simultaneous induction of two DSBs can lead to deletions, inversions and translocations of the intervening segment **(A)**. Gene disruption by short insertion or deletion **(B)**. Gene deletion **(C)**. Gene inversion **(D)**. Gene insertion (Right) In the presence of a donor plasmid with extended homology, HR can lead to the introduction of single or multiple transgenes to correct or replace existing genes **(E)**. Gene addition **(F)**. Gene addition.](fgene-09-00240-g0005){#F5}

Gene knock-down and silencing approaches {#s3}
========================================

The CRISPR/Cascade 9 technology has revolutionized molecular genetics and the technology may eventually be extensively used for gene functional studies. The efficiency of gene knock-down using the CRISPR/Cascade 9 system varies in relation to length and complementary to the crRNA sequence and the particular location of the gene (Gilbert et al., [@B26]). In the laboratory, the researchers face the choice between cutting-edge technologies and more established methods of RNA interference (RNAi)-mediated knock-down (Chang et al., [@B9]). Small interference RNA (siRNA), plasmid and virus-encoded short hairpin RNA are used in well-established procedures to knock-down target genes post-transcriptionally. By binding to the target mRNA, a siRNA will decrease stability and translation. The siRNA can be synthesized from a vector encoding a shRNA, an artificial RNA molecule containing a hairpin that is processed into the mature siRNA by the recipient cell enabling large-scale gene knockdown screening (Wang et al., [@B88]). Similarly, by producing a library of sgRNA targeting specific gene coding regions, the CRISPR/Cascade 9 systems can be used to screen for genes involved in molecular network. Recently, it was shown that Cas13a from *Leptotrichia wadei* enables targeted knock-down of RNA transcripts in bacteria, plant cells, and mammalian cells with an efficiency similar to that obtained by RNA interference, but with higher specificity. This approach can be applied for genome-wide knockdown screening, interrogation of lncRNA and nascent transcript function, including allele-specific knockdown, and RNA viral therapeutics (Abudayyeh et al., [@B1])

The CRISPR/Cascade 9 system using catalytically inactive Cascade 9 is able to deliver 46--63% gene silencing in *HEK293* cells and exhibits even higher efficiency in *E. coli* (Qi et al., [@B70]). Although studies using CRISPR/Cascade 9 technology for complete gene knock-out may reveal more clear phenotypes and less false readouts compared with the variable knock-down of expression using RNAi, the efficiency of the CRISPR/Cascade 9 system is limited by the delivery of Cas9 and synthesis of guide RNA (gRNA) and further improvement is still needed.

Off-target effects {#s4}
==================

Off-target effects represent one of the major challenges as Cascade 9 may recognize sequences with up to 5 mismatched bases. This means that off-target effects may occur to a higher rate than observed using other methods for genome editing. Some approaches to understand and overcome this limitation exist. Recent studies have revealed that DNA-RNA chimeric guides may provide a new strategy to reduce cost and off-target effects in human cells. Cpf1, a single RNA endonuclease utilizes a T-rich PAM on the 5′ side of the guide (Zetsche et al., [@B106]). Cpf1 originates from *Acidaminococcus* sp and a Cpf1-crRNA with an eight nucleotides DNA replacement at the 3′ end was produced. HEK293T cells were transfected with a plasmid expressing the Cpf1 protein followed by crRNAs after 24 h. This experiment showed that the Cpf1 crRNA with partial DNA replacement reduced off target effect in human cells (Yin et al., [@B101]). Novel ways to increase the targeting specificity and reduced off-target effects are actively pursued. Thus, it was reported that specific point mutations increased the specificity of SpCascade 9 (Kleinstiver et al., [@B39]). Similarly, CRISPR structure-guided rational designs have resulted in Cascade 9 variants with increased targeting specificity (Hsu et al., [@B34]). Studies aimed to re-engineer the Cascade 9 structure and alternative targeting approaches to reduce off-target effects are on-going. These efforts include deep sequencing of single targeted sequences in the genome to detect off-target loci, modification of guide RNA and Cascade 9 (Cho et al., [@B11]) as well as correcting off-target mutations by back crossing to the wild-type (Bassett and Liu, [@B5]). Further, studies have shown that nick Cascade 9 can improve the specificity of target recognition in mammalian cell (Fujii et al., [@B21]) and a double-nicking strategy can reduce off-target effects of Cascade 9 (Ran et al., [@B71]). Finally, one study reported that paired Cascade 9 nickases, composed of D10A Cascade 9 and guide RNA, which produce two single-strand breaks (SSBs) or nicks in the DNA strands, were highly specific in human cells, avoiding off-target mutations without sacrificing genome-editing efficiency demonstrating that such strategy could be effective for genome editing without significant off-target effects (Cho et al., [@B12]).

In conclusion, reducing off-target effects may expand the applications of this gene-editing technology (Kleinstiver et al., [@B39]). To achieve this goal, more studies to understand the off-target mechanism and better design of sgRNA are important and deep sequencing analysis or high-throughput sequencing of numerous sgRNAs may provide important information regarding potential off-targets associated with the CRISPR/Cascade 9 system.

Conclusions and perspectives {#s5}
============================

Despite the success achieved by the use of ZFNs, TALENs, and the RNA-guided Cascade 9 system, important challenges related to the effectiveness, specificity, and safety of the CRISPR/Cascade 9 system remain. In addition, the optimal RNA scaffold of CRISPR/Cascade 9 for application in several eukaryotic systems is not known. It also remains to comprehensively evaluate off-targets of Cascade 9 nucleases in the genome of interest. In this context, construction of novel versions of Cascade 9 or sgRNAs/crRNAs may improve the on- and off-target ratio. A system identified in the bacterium *Neisseria meningitides* and uses a longer recognition sequence was recently described (Zhang et al., [@B108]). Finally, it has been suggested that lower concentrations of CRISPR/Cascade 9 reagents in cell diminished cleaving at off-target sites compared to cleaving at on-target sites (Pattanayak et al., [@B64]). To transform the future of genetic biology, an in-depth analysis of ZFN, TALENs, or CRISPR/Cascade 9 systems based on visualization, detection and purification of protein is needed, but so far the CRISPR/Cascade 9 system seems to be the system of choice. Thus, detailed studies of gene function by using the CRISPR/Cascade 9 system have provided novel insight indicating that the CRISPR/Cascade 9 system has the potential to become the key genome editing tool in modern biology (Table [1](#T1){ref-type="table"}). However, further investigations into the CRISPR/Cascade 9 system are clearly required to determine its effectiveness in generating a versatile and heritable modification of target genes, specifically in animals and plants, and more knowledge clearly is needed, and optimization for different cell types and organisms will be required prior to therapeutically and clinical applications.

During transfection or micro-injection with standard viral vectors some cells or tissues could be refractory. Hence, it is a challenge to develop methods securing specific and effective expression of the Cascade 9 nuclease and/or the sgRNAs for each cell type or developmental stage. Additionally, ensuring that a single vector efficiently expresses numerous gRNAs would expand the use of the CRISPR/Cascade 9 systems. Altogether, such improvements would be very important in relation to research and therapeutic applications. Improving methods to specifically change the structure or function of a given gene will allow reverse genetics approaches for any cell type or organism of interest. Still, the levels of Cascade 9 off-target effects remain a problem and the attempts to improve specificity are of importance. The recently developed catalytically dead Cascade 9 (dCas9) 9-targeted somatic hypermutation (a strategy known as CRISPR-X) technology for protein engineering enables specific mutation of endogenous targets with limited off-target damage and is a potentially powerful new approach to investigate the relationship between drug and protein (Hess et al., [@B32]).

The CRISPR/Cascade 9 technique was recently used to remove porcine endogenous retroviruses (PERVs) from the porcine genome, an achievement of importance in relation to future organ transplantation from pigs to human. However, more work regarding safety of cross-species viral transmission is required (Niu et al., [@B60]). One interesting CRISPR application relates to "gene drive" that can target whole population or a species. Here it has been demonstrated that a gene allele that confers a parasite-resistant phenotype in mosquitos can rapidly spread into the population in a non-Mendelian fashion (Gantz et al., [@B22]; Hammond et al., [@B29]).

Genome editing technology has emerged as a promising field in relation to medical applications, but guidelines for designing preclinical trials studies and ethical issues surrounding genome editing and genomic analysis at a population level remain to be established. Thus, the ethical issues regarding the application of the CRISPR/Cascade 9 system in relation to gene therapy are huge (Cyranoski, [@B18]; Lanphier et al., [@B44]; Ma et al., [@B57]). Ethical issues comprise problems of safety, setups in clinical trials, and the criteria for including patients for research and treatment. Key ethical questions in relation to gene therapy in clinical trials also include decisions on criteria for when to implement a new concept in gene therapy where the long term consequences are unknown. Such ethical issues are of paramount importance and the involvement of and accept from the public before instigating such radical novel modalities for treatment of human diseases represent a genuine challenge.

Since the development of the CRISPR/Cascade 9 system, novel opportunities in the field of biomedical research have emerged. However, the effectiveness, accuracy, resolution, and genetic mutation variation still depend on several factors including sgRNA design, DSB introduced, and quantity of nuclease. The safety of the Cascade 9 system for introduction of heritable modifications of specific genes in plants and animals remains to be fully elucidated. Especially, the off-target effects of this system remain to be determined on a large genome-wide scale. Attention clearly needs to be devoted to future applications such as gene therapy and drug screening in the medical field. While the CRISPR/Cascade 9 technology has proven its applicability within numerous lines of basic research, ethical issues as discussed above are needed to be addressed and internationally accepted guidelines need to be adopted for the further use of this technology for genome editing in humans.
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